title: Nateglinide versus repaglinide for type 2 diabetes mellitus in China.
abstract: The purpose of this study is to evaluate efficacy and safety of nateglinide tablet administration in comparison with those of repaglinide tablet as control on treating type 2 diabetes mellitus in China. Pooled-analysis with analysis of covariance (ANCOVA) method was applied to assess the efficacy and safety based on original data collected from four independent randomized clinical trials with similar research protocols. However meta-analysis was applied based on the outcomes of the four studies. The results by meta-analysis were comparable to those obtained by pooled-analysis. The means of HbA(1c), and fasting blood glucose in both the nateglinide and repaglinide groups were reduced significantly after 12 weeks duration but no statistical differences in reduction between the two groups. The adverse reaction rates were 9.89 and 6.51% in the nateglinide and repaglinide groups respectively, with the rate difference showing no statistical significance, and the Odds Ratio of adverse reaction rate (95% confidence interval) was 1.59 (0.99, 2.55). Both nateglinide and repaglinide administration have similarly significant effects on reducing HbA(1c) and FBG. However, the adverse reaction rate in the nateglinide group is higher than that in the latter using repaglinide but no statistical significance difference as revealed in the four clinical trials detailed below.
authors.affiliation: Department of Health Statistics, Fourth Military Medical University, No 17, Changle West Road, 710032, Xi'an, Shaanxi, China.
authors.forename: Chanjuan
authors.initials: C
authors.lastname: Li
authors.forename: Jielai
authors.initials: J
authors.lastname: Xia
authors.forename: Gaokui
authors.initials: G
authors.lastname: Zhang
authors.forename: Suzhen
authors.initials: S
authors.lastname: Wang
authors.forename: Ling
authors.initials: L
authors.lastname: Wang
mesh_terms: D002219:Carbamates / Q000008:administration & dosage* / Q000009:adverse effects; D002681:China; D003510:Cyclohexanes / Q000008:administration & dosage* / Q000009:adverse effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D000077715:Nateglinide; D010649:Phenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010880:Piperidines / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D002219:Carbamates; D003510:Cyclohexanes; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000077715:Nateglinide; D010649:Phenylalanine; D010880:Piperidines; C517652:hemoglobin A1c protein, human; C072379:repaglinide